News

 

  Since its establishment, Sysmex has focused on the hematology field, which involves the testing of blood samples to determine the number, types and sizes of white, red and other blood cells they contain, determining patient health through measurement and analysis. The Company has grown to become the global market leader in the hematology field.

 

  The newly launched XN-Series provides a body fluid measurement mode and increases measurement accuracy for low platelet counts, associated with such diseases as thrombocytopenia, to enhance clinical value. 

  On the usability front, the series embraces the modular concept.^*1 This series allows the combination of multiple analyzers, transportation system, smear preparation system and other instruments. This flexibility enables the proposal of tailored solutions to meet individual customer needs. We have also incorporated into our product portfolio the concept of Silent Design®,^*2 a human-centered design product design concept that takes operator motion into account. This resulted in significant improvements in operability, such as through the simplification of operating panels. The compact design of the series has reduced the footprint of the top-of-the-line transportation system approximately 20%^*3 compared with previous models.

 

  In addition, the XN-Series features further enhancements in online service. Connection to the SNCS®^*4 allows online monitoring of operating conditions by analyzing sensors mounted on the instrument's components. Through such preventive maintenance, we aim to pre-empt sudden malfunctions. 

  Using the combination of 25x concentrated reagents and the RU-20 reagent preparation unit greatly reduces the changing frequency of certain reagents. This is a particular boon for commercial labs and university hospitals that process high volumes of tests each day, by boosting operating efficiency and requiring less reagent storage space. Out of environmental consideration, we have also switched from polyethylene to paper packaging.

 

  By leveraging our strengths to deliver additional value, we aim to secure our position as the undisputed global leader in hematology. As the frontrunner, we will continue to employ advanced technologies. Through these proactive efforts, combined with ongoing R&D initiatives, we aim to play a leading role in the next-generation hematology market and sustain our growth into the future.